More about

Major Depressive Disorder

News
August 24, 2023
2 min read
Save

Deep brain stimulation may provide long-term benefits in treatment-resistant depression

Deep brain stimulation may provide long-term benefits in treatment-resistant depression

Subcallosal cingulate gyrus deep brain stimulation was generally safe and significantly improved depressive symptoms in patients with treatment-resistant depression, with results sustained up to 7 years, according to research.

News
August 01, 2023
1 min read
Save

Partnership to advance development of psychedelics for depression, anxiety

Partnership to advance development of psychedelics for depression, anxiety

A clinical-stage biopharmaceutical company and a global contract research organization have partnered to support the ongoing development of investigational, psychedelic therapeutics to treat a range of psychiatric disorders.

News
July 28, 2023
1 min read
Save

Oral monotherapy for major depressive disorder entering phase 3 trials

Oral monotherapy for major depressive disorder entering phase 3 trials

monotherapy for the treatment of major depressive disorder, is set to enter a phase 3 clinical program, with a new drug application expected in 2025, according to a press release.

News
July 14, 2023
2 min read
Save

AbbVie committed to extending clinical value of its therapeutics

AbbVie committed to extending clinical value of its therapeutics

BOSTON — With a multitude of products spanning neuroscience and psychiatry, executives at AbbVie say they are committed to learning the full clinical value of all of the company’s products for the benefit of patients.

News
July 11, 2023
1 min read
Save

Symptom dimensions within bipolar disorder may have distinct causes

Symptom dimensions within bipolar disorder may have distinct causes

Symptom dimensions within bipolar disorder may have distinct causes, supporting the hypothesis that genetic heterogeneity underpins clinical heterogeneity, according to a study published in The Lancet Psychiatry.

News
July 07, 2023
1 min read
Save

Esketamine ‘effective and well-tolerated’ for adolescents with MDD, suicidal ideation

Esketamine ‘effective and well-tolerated’ for adolescents with MDD, suicidal ideation

Esketamine is an effective and well-tolerated treatment option for adolescents with major depressive disorder and suicidal ideation, according to a study published in the Journal of the American Academy of Child & Adolescent Psychiatry.

News
June 27, 2023
1 min read
Save

Positive results from phase 1 study of nasal spray for MDD allows US phase 2b trial development

Positive results from phase 1 study of nasal spray for MDD allows US phase 2b trial development

A biopharmaceutical company has announced positive safety and tolerability data from a United States-based phase 1 clinical trial of its investigational rapid-onset pherine nasal spray to treat major depressive disorder.

News
June 12, 2023
2 min read
Save

Zuranolone linked to improved depression scores, longer repeat treatment intervals in MDD

Zuranolone linked to improved depression scores, longer repeat treatment intervals in MDD

MIAMI BEACH, Fla. — For adults with major depressive disorder, treatment with zuranolone was linked to improvements in self-reported depressive symptoms, longer repeat treatment intervals and was generally well-tolerated.

News
May 31, 2023
2 min read
Save

Aticaprant shows symptom improvement as adjunctive treatment in MDD

Aticaprant shows symptom improvement as adjunctive treatment in MDD

MIAMI BEACH, Fla. — Adjunctive treatment with aticaprant for those with major depressive disorder and history of antidepressant failure resulted in greater symptom improvement compared with placebo after 6 weeks, a presenter said.

News
May 22, 2023
2 min read
Save

Deep TMS improves quality of life in treatment-resistant depression

Deep TMS improves quality of life in treatment-resistant depression

SAN FRANCISCO — For patients with treatment-resistant major depressive disorder, deep transcranial magnetic stimulation significantly improved symptoms and quality of life compared with sham, according to a poster presented here.

View more